166 results
8-K
EX-10.3
LRMR
Larimar Therapeutics Inc
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
, 2017, by and between Zafgen, Inc., a Delaware corporation (the “Company”), and Jeffrey Hatfield (the “Employee”). Capitalized terms not defined herein … the Employee, to their assigned duties without distraction, including in the face of potentially disturbing circumstances arising from the possibility
8-K
EX-10.3
LRMR
Larimar Therapeutics Inc
12 Sep 19
Cost Associated with Exit or Disposal Activities
5:19pm
. McVeigh (the “Employee”).
WHEREAS, the Company and the Employee are parties to a Severance and Change in Control Agreement dated as of May 29, 2018 … (the “Severance and Change in Control Agreement”);
WHEREAS, the Company and the Employee wish to amend certain provisions of the Severance and Change
8-K
EX-10.2
dno46m1v4c7w
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
8-K
EX-2.1
ufdplzj6
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
8-K
EX-10.1
t483pu0ft
12 Sep 19
Cost Associated with Exit or Disposal Activities
5:19pm
8-K
EX-10.2
fazxesg 58
12 Sep 19
Cost Associated with Exit or Disposal Activities
5:19pm
8-K
EX-10.1
2aj3eh9
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
S-1
EX-10.10
jkvuz
18 Apr 14
IPO registration
12:00am
8-K
r0ftoebfd iqj
30 Sep 15
Zafgen Announces Transition of Board of Directors
12:00am
S-1
EX-10.6
l0n1675 51zsk
18 Apr 14
IPO registration
12:00am